Details of the Drug Combination

General Information of Drug Combination (ID: DCX9X3O)

Drug Combination Name

Mebutamate Trimethobenzamide

Indication

Disease Entry	Status	REF
Chronic myelogenous leukemia	Investigative	[1]

Component Drugs

Mebutamate DM0KYI4

Trimethobenzamide DMPP4DT

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: KBM-7

Zero Interaction Potency (ZIP) Score: 22.36

Bliss Independence Score: 22.36

Loewe Additivity Score: 29.78

LHighest Single Agent (HSA) Score: 29.83

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Mebutamate

Disease Entry	ICD 11	Status	REF
Anxiety disorder	6B00-6B0Z	Approved	[2]

Mebutamate Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
GABA(A) receptor gamma-3 (GABRG3)	TTEX6LM	GBRG3_HUMAN	Modulator	[4]
------------------------------------------------------------------------------------

Indication(s) of Trimethobenzamide

Disease Entry	ICD 11	Status	REF
Nausea	MD90	Approved	[3]
Nausea and vomiting	MD90	Approved	[2]
Vomiting	MD90	Approved	[3]

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Trimethobenzamide FDA Label
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.